Drug intelligence / Profile preview

PF-05161704

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-05161704 is an orally available small molecule that was developed by Pfizer for the treatment of type 2 diabetes mellitus. It was classified as an antihyperglycemic agent, but its precise mechanism of action remains undefined in public sources. The drug advanced to phase 1 clinical trials, where it was evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers. Development of PF-05161704 for type 2 diabetes mellitus was discontinued after phase 1 trials[1][2][3][4][5][7].

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on PF-05161704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-05161704.

Explore the full profile